BofA Raises Snowflake Price Target to $205, Expects Strong Q1 Earnings
Bank of America raised its Snowflake target to $205, kept a Buy rating, and expects strong results.
Already have an account? Sign in.
Bank of America raised its Snowflake target to $205, kept a Buy rating, and expects strong results.
AbbVie’s Phase 3 HS data fell short of expectations, prompting two firms to downgrade Avalo Therapeutics and lower confidence in IL-1 approaches.
Shares of Aardvark Therapeutics dropped after limited HERO data showed only temporary benefit for ARD-101 in Prader-Willi syndrome, delaying restart to 2027.
BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.
Be the first to know when deals break, stocks move, or biotech headlines hit.